Table 4.
Summary of differences and similarities between BCOR‐ITD sarcomas of all localisations
| Clinical data | Histology | Radiology | Molecular biology | ||||
|---|---|---|---|---|---|---|---|
| Age, median (range)) | Prognosis # deceased mean delay | Mitotic counts per 10 hpf (range) | Immunostaining | (features apply to all tumour types) | DEGs | ||
| BCOR‐ITD sarcomas | CCSK | 2.0 (0.5–18.9) | 0/7 | 0–18 |
BCOR SATB2, Cyclin D1, BCL2, TLE1 WT1‐neg, SMARCB1 + |
Heterogeneous masses Necrosis Haemorrhage Low‐to‐moderate contrast enhancement |
NTRK3 EGFR PDGFRa |
| HG‐ESS | 51.1 (25.8–62.4) |
2/4 36 months |
14–21 |
BCOR SATB2, Cyclin D1, BCL2, TLE1 Desmin‐neg, Caldesmon‐neg |
|||
| URCS | 0.7 (0.1–19.7) |
4/8 31 months |
1.7–13.7 |
BCOR SATB2, Cyclin D1, BCL2, TLE1 |
|||
| BCOR‐ITD CNS tumours | HGNET‐BCOR | 1.8 (1.2–7.6) |
6/10 28 months |
5–62 |
BCOR SATB2, Cyclin D1, BCL2, TLE1 NeuN GFAP+/−, Olig2 +/− |
NTRK2 Wnt7b PDGFRa |
|
hpf, high‐power field.